NKGen Biotech (NKGN) Competitors $0.26 +0.00 (+0.85%) As of 01:40 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NKGN vs. RENB, VTVT, QNTM, APLT, ADVM, DTIL, ALGS, ANVS, GANX, and PRLDShould you be buying NKGen Biotech stock or one of its competitors? The main competitors of NKGen Biotech include Renovaro (RENB), vTv Therapeutics (VTVT), Quantum Biopharma (QNTM), Applied Therapeutics (APLT), Adverum Biotechnologies (ADVM), Precision BioSciences (DTIL), Aligos Therapeutics (ALGS), Annovis Bio (ANVS), Gain Therapeutics (GANX), and Prelude Therapeutics (PRLD). These companies are all part of the "pharmaceutical products" industry. NKGen Biotech vs. Its Competitors Renovaro vTv Therapeutics Quantum Biopharma Applied Therapeutics Adverum Biotechnologies Precision BioSciences Aligos Therapeutics Annovis Bio Gain Therapeutics Prelude Therapeutics NKGen Biotech (NYSE:NKGN) and Renovaro (NASDAQ:RENB) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk. Does the media refer more to NKGN or RENB? In the previous week, NKGen Biotech had 3 more articles in the media than Renovaro. MarketBeat recorded 6 mentions for NKGen Biotech and 3 mentions for Renovaro. Renovaro's average media sentiment score of 0.07 beat NKGen Biotech's score of 0.00 indicating that Renovaro is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NKGen Biotech 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Renovaro 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable earnings & valuation, NKGN or RENB? Renovaro is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNKGen BiotechN/AN/A-$82.94M-$2.45-0.11RenovaroN/AN/A-$88.43M-$0.77-0.43 Do institutionals & insiders believe in NKGN or RENB? 76.2% of NKGen Biotech shares are held by institutional investors. Comparatively, 71.4% of Renovaro shares are held by institutional investors. 10.4% of NKGen Biotech shares are held by insiders. Comparatively, 21.7% of Renovaro shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is NKGN or RENB more profitable? NKGen Biotech's return on equity of 0.00% beat Renovaro's return on equity.Company Net Margins Return on Equity Return on Assets NKGen BiotechN/A N/A -479.36% Renovaro N/A -60.38%-47.04% Which has more risk and volatility, NKGN or RENB? NKGen Biotech has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500. Comparatively, Renovaro has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500. SummaryNKGen Biotech beats Renovaro on 6 of the 10 factors compared between the two stocks. Get NKGen Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for NKGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NKGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NKGN vs. The Competition Export to ExcelMetricNKGen BiotechBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$11.79M$269.09M$5.51B$20.71BDividend YieldN/AN/A4.25%3.68%P/E Ratio-0.05N/A28.2727.42Price / SalesN/A429.39424.8970.78Price / CashN/A22.4435.5321.88Price / Book-0.109.668.214.64Net Income-$82.94M-$110.10M$3.24B$994.58M7 Day Performance-12.60%-4.79%0.43%-0.94%1 Month Performance-8.80%10.81%7.84%5.16%1 Year Performance-71.99%20.44%28.19%8.80% NKGen Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NKGNNKGen Biotech0.2657 of 5 stars$0.26+0.8%N/A-71.0%$11.79MN/A-0.05N/ANews CoverageGap UpRENBRenovaro2.1084 of 5 stars$0.31+3.3%N/A-76.1%$52.72MN/A-0.4020Gap UpVTVTvTv Therapeutics1.7655 of 5 stars$16.25+9.1%$35.50+118.5%-30.3%$51.84M$1.02M-5.409News CoveragePositive NewsQNTMQuantum BiopharmaN/A$17.47+5.5%N/AN/A$50.80MN/A-1.09N/AAPLTApplied Therapeutics4.5491 of 5 stars$0.36+6.8%$6.10+1,602.5%-92.2%$50.73M$460K-0.8330Positive NewsADVMAdverum Biotechnologies4.4032 of 5 stars$2.41+8.1%$23.80+887.6%-69.1%$50.35M$1M-0.38190DTILPrecision BioSciences4.2971 of 5 stars$4.52+4.9%$47.00+939.8%-56.5%$50.13M$68.70M-2.25200ALGSAligos Therapeutics4.1607 of 5 stars$8.17+8.9%$70.00+756.8%-34.0%$49.92M$3.94M-0.4790ANVSAnnovis Bio1.5704 of 5 stars$2.56+8.5%$18.00+603.1%-77.6%$49.89MN/A-1.193GANXGain Therapeutics2.3162 of 5 stars$1.67+4.1%$8.20+392.5%+24.6%$49.87M$50K-1.9420News CoveragePRLDPrelude Therapeutics3.7073 of 5 stars$0.88+9.1%$4.50+411.4%-86.8%$49.69M$7M-0.52120Positive News Related Companies and Tools Related Companies Renovaro Alternatives vTv Therapeutics Alternatives Quantum Biopharma Alternatives Applied Therapeutics Alternatives Adverum Biotechnologies Alternatives Precision BioSciences Alternatives Aligos Therapeutics Alternatives Annovis Bio Alternatives Gain Therapeutics Alternatives Prelude Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:NKGN) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NKGen Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NKGen Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NKGN Stock Alerts